Ichorcumab - Janssen Pharmaceuticals

Drug Profile

Ichorcumab - Janssen Pharmaceuticals

Alternative Names: JNJ 9375; JNJ-375; JNJ-64179375

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge University Hospitals; University of Cambridge
  • Developer Janssen Pharmaceuticals
  • Class Anticoagulants; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thrombosis

Most Recent Events

  • 25 Jun 2018 Janssen Research & Development completes a phase I trial in Healthy volunteers in United Kingdom (IV) (SC) (NCT03080987)
  • 09 Dec 2017 Pharmacodynamics data from preclinical studies in Thrombosis presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
  • 15 Nov 2017 Phase-II clinical trials in Thrombosis (Prevention) in Belgium, Spain, Sweden (IV) (NCT03251482)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top